Company Profiles

driven by the PitchBook Platform

Aravax

Aravax
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
$4.85M LATEST DEAL AMOUNT
$4.85M TOTAL AMOUNT RAISED
Description

Developer of a vaccine to treat peanut allergies. The company engages in the development of a vaccine which resets the immune system to tolerate peanuts without evoking allergic reactions.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
Level 9, 278 Collins Street
Melbourne, Victoria 3000
Australia

+61 (0)3 9657 0700
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aravax’s full profile, request a free trial.

Aravax Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 22-Nov-2015 $4.85M $4.85M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Aravax Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Brandon Capital Partners Venture Capital Minority 000 0000 000000 0

You’re viewing 1 of 1 investors.

Aravax Executive Team (2)

Name Title Board
Seat
Contact
Info
Sara Prickett Ph.D Chief Operating Officer & Co-Founder
Robyn O'Hehir Chief Scientific Officer & Co-Founder

You’re viewing 2 of 2 executives.

Aravax Board Members (2)

Name Representing Role Since Contact
Info
Christopher Smith Brandon Capital Partners Board Member 000 0000
Fiona Miles Aravax Board Member 000 0000

You’re viewing 2 of 2 board members.